Related trials
BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent
GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent
RESOLUTE, 2010 - zotarolimus eluting stent vs everolimus eluting stent
SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent
SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent
BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent
ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent
Thiele, 2009 - sirolimus ES vs MIDCAB
ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent
NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis
ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent
ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent
SYNTAX, 2009 - paclitaxel eluting stent vs CABG
Juwana, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
PASEO, 2009 - drug-eluting stents vs bare-metal stent
ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent
DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent
ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
See also:
All coronary artery disease clinical trials
All acute myocardial infarction clinical trials
All clinical trials of PCI
All clinical trials of sirolimus eluting stent
|
|
Treatments
Studied treatment |
sirolimus-eluting stents
|
Control treatment |
bare-metal stents
|
Concomittant treatment |
Aspirin (160 mg), clopidogrel (600 mg), and unfractionated heparin (5000 U bolus)
|
Remarks |
factorial design: sirolimus-eluting stents (SES) vsbare-metal stents (BMS), and abciximab vs no abciximab |
Patients
Patients |
patients undergoing PCI for STEMI withon 12 hours |
Exclusion criteria |
contraindications for abciximab, clopidogrel, or stenting; glycoprotein IIb/IIIa inhibitors within 24h; thrombolytic therapy within 24h |
Baseline characteristics |
age |
60y |
diabetes (%) |
10% |
Female (%) |
24% |
|
Method and design
Randomized effectives |
424 / 446 (studied vs. control) |
Design |
Factorial plan |
Follow-up duration |
1 y |
Primary endpoint |
TVF( TV MI, TVR, stent thrombosis, in-stent restenosis) |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
angiographic restenosis
8 / 424
27 / 446
0,31 [0,14;0,68]
2 yr MACE
55 / 424
89 / 446
0,65 [0,48;0,89]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
angiographic restenosis
|
8 / 424 (1,9%) |
27 / 446 (6,1%) |
0,31 |
[0,14;0,68] |
in stent restenosis at 1y |
|
2 yr MACE
|
55 / 424 (13,0%) |
89 / 446 (20,0%) |
0,65 |
[0,48;0,89] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
angiographic restenosis |
1,89% |
6,05% |
-41,7‰
|
2 yr MACE |
12,97% |
19,96% |
-69,8‰
|
Meta-analysis of all similar trials:
Drug eluting stent in coronary artery disease for acute myocardial infarction
Drug eluting stent in coronary artery disease for all type of patients
PCI in acute myocardial infarction for all type of patients
Reference(s)
|